Peptide-S Safety Rating & Test Results
As of 25 Jul 2026, Finnrick has published 128 independent lab tests of 11 peptides from Peptide-S: 87 passed, 37 failed, and 4 were not classifiable (incomplete data) under the default public standard, Purity Focus (HPLC purity at least 99.5%, fill within ±35% of the label claim). The latest test is dated 10 Mar 2026.
Finnrick ratings are recency-weighted pass percentages: newer tests count more, and vendors with thin test histories are pulled toward the peer baseline for that peptide, so a single result cannot look too certain. Samples are analyzed by independent partner laboratories and the results are published by Finnrick Analytics, which does not sell peptides and does not accept payment to alter ratings. Corrections to published data are recorded at finnrick.com/corrections.
Purchased from Peptide-S? Submit a sample to Finnrick for free independent lab testing — results are published publicly.
Are you Peptide-S? Finnrick offers professional testing services and a public launch program for peptide vendors.
Interactive charts, prices, and test history for this page load with JavaScript; the facts above are from Finnrick's published test database.
| Peptide | Finnrick rating | Lab tests | Latest test |
|---|---|---|---|
| BPC-157 | 52% | 5 | 18 Sept 2025 |
| Cagrilintide | 50% | 4 | 25 Nov 2025 |
| GHK-Cu | 93% | 9 | 22 Feb 2026 |
| Ipamorelin | 71% | 4 | 20 Feb 2026 |
| Mazdutide | 68% | 4 | 25 Nov 2025 |
| Retatrutide | 69% | 42 | 10 Mar 2026 |
| Semaglutide | 72% | 6 | 15 Jan 2026 |
| Sermorelin | 34% | 3 | 20 Feb 2026 |
| Survodutide | 66% | 4 | 25 Nov 2025 |
| Tesamorelin | 37% | 7 | 15 Jan 2026 |
| Tirzepatide | 85% | 40 | 2 Mar 2026 |